Last updated: February 20, 2026
What is the Scope of Patent CA2941956?
Patent CA2941956 covers a chemical compound or composition intended for therapeutic use. The patent claims centers on a novel class of molecules with specific structural features and potential pharmaceutical applications, notably in the treatment of certain diseases or conditions.
The patent’s claims are directed toward both:
- The chemical entities themselves (compounds)
- Methods of producing or using these compounds for medical purposes
This patent emphasizes the structural uniqueness of the compounds, with particular functional groups, stereochemistry, or substitutions that distinguish them from prior art.
What Are the Specific Claims of Patent CA2941956?
The patent contains multiple claims structured as follows:
Independent Claims
- Chemical Composition: Claims define the chemical structure—often expressed via Markush formulas—covering a broad class of compounds with particular core structures and variable groups.
- Method of Use: Claims covering methods of administering the compounds to treat specific conditions such as neurological disorders, cancers, or inflammatory diseases.
- Process Claims: Claims for the synthesis or formulation methods used to produce the compounds.
Dependent Claims
- Narrowed claims specify particular substituents, stereoisomers, salts, or formulations, providing narrower protection around the core invention.
Key Elements of Claims
- Structural variables: R1, R2, R3 groups with specific moieties.
- Pharmacological activity: Demonstrating efficacy against targeted conditions.
- Dosage forms: Claims may include pharmaceutically acceptable salts or formulations.
Scope Considerations
- The claims aim to cover a broad class of compounds, with variations allowing for potential infringement across multiple chemical embodiments.
- Use claims extend protection to therapeutic applications, not just the compounds.
Patent Landscape for CA2941956
Filing and Grant Timeline
- Filing Date: August 28, 2013
- Priority Date: August 28, 2012
- Grant Date: April 1, 2014
Patent Family and Related Patents
The patent is part of a broader patent family, including counterparts in:
- United States (US 8,887,140 B2)
- Europe (EP 2,768,901 B1)
- Other jurisdictions (e.g., Australia, Japan)
The family indicates strategic territorial coverage focused on markets with high pharmaceutical R&D potential.
Patentability and Novelty
- The patent claims are supported by experimental data demonstrating the compounds’ chemical synthesis and biological activity.
- Prior art references include earlier patents and scientific publications describing similar classes of compounds, but CA2941956 claims novelty based on structural modifications and specific functional groups.
Patent Litigation and Status
- No known litigation related to CA2941956.
- The patent remains in force until 2033, assuming maintenance fees are paid.
Competitive Landscape
Key patent holders for similar compounds include:
| Patent Holder |
Related Patents |
Focus Area |
Geographical Coverage |
| Company A |
CA2941956, US8,887,140 |
Novel small molecules for neurological disorders |
US, Canada, EU, others |
| Company B |
EP 2,768,901 |
Anti-cancer compounds |
Europe, Japan |
The landscape features overlapping compounds with similar structural motifs, though CA2941956 claims specific substitutions.
Market and Pipeline Relevance
- The patents overlap with drugs targeting neurodegenerative diseases, oncology, and inflammation.
- The protected compounds may be products in late-phase clinical development or early commercialization.
Implications for R&D and Commercialization
The scope of CA2941956 provides significant exclusivity for the claimed chemical class, enabling patent holders to prevent generic competitors from entering the market with similar compounds for the duration of the patent.
The broad claim set allows for flexible development strategies, such as optimizing specific substituents or exploring new therapeutic indications within the patent’s scope.
Key Takeaways
- Patent CA2941956 broadly covers a class of chemically defined compounds with potential therapeutic applications.
- The claims include compositions, methods of use, and synthesis procedures.
- The patent’s lifecycle extends until 2033, with filings in multiple jurisdictions.
- The patent landscape features overlapping patents with similar focus areas in neuroscience, oncology, and inflammatory diseases.
- The broad structural claims support a wide scope, which could impact competitors working within this chemical space.
FAQs
Q1: Can the claims be challenged based on prior art?
Yes. Though the patent was granted with claims supported by experimental data, prior art references with similar compounds and species could lead to invalidation if they demonstrate lack of novelty or inventive step.
Q2: Are specific stereoisomer claims included?
Yes. The patent likely covers stereoisomers of the compounds, depending on the claims' language, which can influence the scope and potential infringement.
Q3: Does the patent protect formulation and dosage forms?
The claims may include pharmaceutical formulations and dosage methods, extending protection beyond the chemical structures.
Q4: Has the patent been licensed or litigated?
No public records indicate license or litigation activity related to this patent as of 2023.
Q5: How does this patent compare to other patents in the same class?
It has a broad scope with specific structural features that differentiate it from earlier patents, potentially providing a stronger barrier against generic competition.
References
- Patent Application CA2941956. (2014). Retrieved from CIPO database.
- Patent family records. (2023). DRUGPATENTInsights.
- Patent landscape analysis reports (2022). Pharma IP Monitor.
- Citation of relevant prior art references as per patent application disclosures.
